Developer docs
API playgroundTry for free, no card

Search company profiles

Icosavax

Full company profile

uuid0000ofr

Namestring
Icosavax
Legal namestring
Icosavax, Inc.
Websiteurl
icosavax.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Icosavax was a Seattle-based, clinical-stage biopharmaceutical company founded in 2017 that developed vaccines against respiratory infectious diseases using a proprietary virus-like particle (VLP) platform. Its lead program, IVX-A12, was a first-in-class bivalent vaccine candidate designed to provide single-immunization protection against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) — two pathogens for which no combination vaccine previously existed. The VLP technology uses self-assembling protein nanoparticles to display target antigens, enabling robust immune responses without live virus, and was supported by computational protein design capability associated with co-founder David Baker.

The company targeted high-need patient populations including infants and young children, immunocompromised individuals, and high-risk adults aged 18-59, addressing prevention gaps in RSV and hMPV where approved vaccines remained limited. Icosavax was venture-backed, raising approximately $235 million across rounds from 2019 to 2023 from a syndicate including RA Capital, Qiming Venture Partners, Sanofi Ventures, Viking Global, Cormorant Asset Management, and the Bill & Melinda Gates Foundation. The company reported positive Phase I data for its RSV program and advanced IVX-A12 into Phase II, presenting interim data at IDWeek 2024.

In February 2024, AstraZeneca acquired Icosavax for approximately $1.1 billion, integrating the VLP platform and IVX-A12 into AZ's respiratory vaccine pipeline. Icosavax did not generate commercial product revenue; its pre-acquisition economics were driven by milestone-based R&D progress and an eventual strategic exit rather than product sales or licensing royalties. Post-acquisition, Icosavax operates as a wholly-owned subsidiary of AstraZeneca with clinical development continuing within AZ's broader vaccines organization.

Short descriptiontext

Icosavax was a Seattle-based clinical-stage biotech developing VLP-based vaccines, led by IVX-A12, a first-in-class bivalent vaccine targeting RSV and hMPV. Founded in 2017, it was acquired by AstraZeneca in February 2024 for approximately $1.1 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
virus-like particle vaccines, respiratory syncytial virus vaccines, combination vaccine candidates, infectious disease vaccines, VLP vaccine platform
Industry2 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAD
Seasonal & Endemic Vaccines (e.g., Influenza)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Infectious Disease Vaccine Development
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Vaccine Development and Commercialization
TypeOne Time License
Description

Pre-acquisition, Icosavax was a clinical-stage biotech developing vaccines. Post-acquisition (February 2024), the company became part of AstraZeneca's portfolio with the RSV/hMPV combination vaccine candidate IVX-A12 advancing through clinical development.

openpr.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Icosavax develops vaccines for infectious diseases using a proprietary virus-like particle (VLP) technology platform. Its primary product candidate, IVX-A12, is a first-in-class bivalent vaccine targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The company was acquired by AstraZeneca in February 2024 for approximately $1.1 billion, with the vaccine candidate continuing clinical development under AstraZeneca.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 90% reduction in RSV-associated hospitalizations among infants (Beyfortus/nirsevimab in first season)
Product overview1 text field

Icosavax is a biopharmaceutical company focused on developing vaccines using virus-like particle (VLP) technology. The company's primary product candidate is IVX-A12, a first-in-class bivalent RSV/hMPV combination vaccine. Following its acquisition by AstraZeneca in February 2024 for approximately $1.1 billion, the IVX-A12 candidate is being advanced through clinical development as part of AstraZeneca's infectious disease vaccines portfolio. Prior to acquisition, Icosavax had raised $67.8 million and reported positive Phase I data for its RSV vaccine program.

Product and service1 record
1IVX-A12
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Novavax uses a recombinant protein nanoparticle (Matrix-M adjuvant) platform that is functionally analogous to Icosavax's VLP technology for vaccines; it is the closest technology and product-category peer.

TypeEmerging player
Description

Bavarian Nordic is a commercial-stage vaccines company focused on infectious diseases with a respiratory/infectious disease pipeline that overlaps Icosavax's therapeutic focus.

TypeBroad incumbent
Description

Sanofi co-developed Beyfortus (nirsevimab), an RSV antibody competing in infant RSV prevention, and was itself an Icosavax investor; Sanofi is a broad incumbent with major respiratory vaccine and biologics portfolio.

TypeEmerging player
Description

CureVac develops mRNA-based vaccines for infectious diseases including respiratory pathogens, making it a comparable technology-and-target peer in the vaccines space.

TypeEmerging player
Description

Arcturus develops mRNA vaccines including for respiratory pathogens (e.g., COVID), positioning it as a technology peer pursuing infectious disease vaccines via a different but related modality.

TypeEmerging player
Description

Meissa is developing a live-attenuated intranasal RSV vaccine, making it an emerging direct competitor in the RSV vaccine space targeting the same indication as IVX-A12.

TypeBroad incumbent
Description

Pfizer's ABRYSVO is an approved RSV vaccine directly competing with IVX-A12's target indication, and Pfizer is a broad incumbent in the vaccines space with global commercial reach.

TypeDirect peer
Description

Vaxcyte develops protein VLP/conjugate vaccine candidates targeting respiratory and bacterial pathogens using a similar structure-based vaccine design approach, making it a direct technology peer.

TypeDirect peer
Description

Moderna is developing mRNA-based RSV vaccines (mResvia is approved) and competing in the same respiratory vaccine market, using a different but adjacent vaccine technology platform.

10GSK
TypeBroad incumbent
Description

GSK's Arexvy is an approved RSV vaccine competing for the same older-adult population; GSK is a broad incumbent in vaccines with established physician relationships and global distribution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Icosavax

Infectious Disease Vaccine Developmenticosavax.com

Icosavax was a Seattle-based clinical-stage biotech developing VLP-based vaccines, led by IVX-A12, a first-in-class bivalent vaccine targeting RSV and hMPV. Founded in 2017, it was acquired by AstraZeneca in February 2024 for approximately $1.1 billion.

What Icosavax does

Icosavax was a Seattle-based, clinical-stage biopharmaceutical company founded in 2017 that developed vaccines against respiratory infectious diseases using a proprietary virus-like particle (VLP) platform. Its lead program, IVX-A12, was a first-in-class bivalent vaccine candidate designed to provide single-immunization protection against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) — two pathogens for which no combination vaccine previously existed. The VLP technology uses self-assembling protein nanoparticles to display target antigens, enabling robust immune responses without live virus, and was supported by computational protein design capability associated with co-founder David Baker.

The company targeted high-need patient populations including infants and young children, immunocompromised individuals, and high-risk adults aged 18-59, addressing prevention gaps in RSV and hMPV where approved vaccines remained limited. Icosavax was venture-backed, raising approximately $235 million across rounds from 2019 to 2023 from a syndicate including RA Capital, Qiming Venture Partners, Sanofi Ventures, Viking Global, Cormorant Asset Management, and the Bill & Melinda Gates Foundation. The company reported positive Phase I data for its RSV program and advanced IVX-A12 into Phase II, presenting interim data at IDWeek 2024.

In February 2024, AstraZeneca acquired Icosavax for approximately $1.1 billion, integrating the VLP platform and IVX-A12 into AZ's respiratory vaccine pipeline. Icosavax did not generate commercial product revenue; its pre-acquisition economics were driven by milestone-based R&D progress and an eventual strategic exit rather than product sales or licensing royalties. Post-acquisition, Icosavax operates as a wholly-owned subsidiary of AstraZeneca with clinical development continuing within AZ's broader vaccines organization.

Icosavax firmographics

Firmographics
Name
Icosavax
Legal name
Icosavax, Inc.
Website
https://icosavax.com
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
51–100 employees
Short description
Icosavax was a Seattle-based clinical-stage biotech developing VLP-based vaccines, led by IVX-A12, a first-in-class bivalent vaccine targeting RSV and hMPV. Founded in 2017, it was acquired by AstraZeneca in February 2024 for approximately $1.1 billion.
Ownership category
akta.pro rank

Icosavax industry classification

Industry
Product category
Infectious Disease Vaccine Development
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAD
Seasonal & Endemic Vaccines (e.g., Influenza)

Keywords

  • Virus-like particle vaccines
  • Respiratory syncytial virus vaccines
  • Combination vaccine candidates
  • Infectious disease vaccines
  • VLP vaccine platform

Where Icosavax is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Markets served

Icosavax business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Vaccine Development and Commercialization: Pre-acquisition, Icosavax was a clinical-stage biotech developing vaccines. Post-acquisition (February 2024), the company became part of AstraZeneca's portfolio with the RSV/hMPV combination vaccine candidate IVX-A12 advancing through clinical development.

Go-to-market motion1 record

Marketing channels1 record

Icosavax product offering

Product offering

Core offering

Icosavax develops vaccines for infectious diseases using a proprietary virus-like particle (VLP) technology platform. Its primary product candidate, IVX-A12, is a first-in-class bivalent vaccine targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The company was acquired by AstraZeneca in February 2024 for approximately $1.1 billion, with the vaccine candidate continuing clinical development under AstraZeneca.

Product overview

Icosavax is a biopharmaceutical company focused on developing vaccines using virus-like particle (VLP) technology. The company's primary product candidate is IVX-A12, a first-in-class bivalent RSV/hMPV combination vaccine. Following its acquisition by AstraZeneca in February 2024 for approximately $1.1 billion, the IVX-A12 candidate is being advanced through clinical development as part of AstraZeneca's infectious disease vaccines portfolio. Prior to acquisition, Icosavax had raised $67.8 million and reported positive Phase I data for its RSV vaccine program.

Differentiator

Problem solved

Functional benefit

Products and services

  • IVX-A12

Quantifiable outcome

  • 90% reduction in RSV-associated hospitalizations among infants (Beyfortus/nirsevimab in first season)

Companies that use Icosavax

Customer profile

Segments3 records

Ideal customer profiles1 record

Icosavax technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Icosavax partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Icosavax competitors and assessment

Company assessment

Direct peers

  • Novavax: Novavax uses a recombinant protein nanoparticle (Matrix-M adjuvant) platform that is functionally analogous to Icosavax's VLP technology for vaccines; it is the closest technology and product-category peer.
  • Vaxcyte: Vaxcyte develops protein VLP/conjugate vaccine candidates targeting respiratory and bacterial pathogens using a similar structure-based vaccine design approach, making it a direct technology peer.
  • Moderna: Moderna is developing mRNA-based RSV vaccines (mResvia is approved) and competing in the same respiratory vaccine market, using a different but adjacent vaccine technology platform.

Emerging players

  • Bavarian Nordic: Bavarian Nordic is a commercial-stage vaccines company focused on infectious diseases with a respiratory/infectious disease pipeline that overlaps Icosavax's therapeutic focus.
  • CureVac: CureVac develops mRNA-based vaccines for infectious diseases including respiratory pathogens, making it a comparable technology-and-target peer in the vaccines space.
  • Arcturus Therapeutics: Arcturus develops mRNA vaccines including for respiratory pathogens (e.g., COVID), positioning it as a technology peer pursuing infectious disease vaccines via a different but related modality.
  • Meissa Vaccines: Meissa is developing a live-attenuated intranasal RSV vaccine, making it an emerging direct competitor in the RSV vaccine space targeting the same indication as IVX-A12.

Broad incumbents

  • Sanofi: Sanofi co-developed Beyfortus (nirsevimab), an RSV antibody competing in infant RSV prevention, and was itself an Icosavax investor; Sanofi is a broad incumbent with major respiratory vaccine and biologics portfolio.
  • Pfizer: Pfizer's ABRYSVO is an approved RSV vaccine directly competing with IVX-A12's target indication, and Pfizer is a broad incumbent in the vaccines space with global commercial reach.
  • GSK: GSK's Arexvy is an approved RSV vaccine competing for the same older-adult population; GSK is a broad incumbent in vaccines with established physician relationships and global distribution.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Icosavax social profiles

Digital presence

Icosavax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Icosavax leadership team

Management profile

Number of profiles

Profiles2 records

Icosavax funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Icosavax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Icosavax

What does Icosavax do?

Icosavax develops vaccines for infectious diseases using a proprietary virus-like particle (VLP) technology platform. Its primary product candidate, IVX-A12, is a first-in-class bivalent vaccine targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The company was acquired by AstraZeneca in February 2024 for approximately $1.1 billion, with the vaccine candidate continuing clinical development under AstraZeneca.

Is Icosavax a public or private company?

Icosavax is a private company. It is classified as corporate owned and is currently acquired.

When was Icosavax founded?

Icosavax was founded in 2017. It employs 51 to 100 people.

Where is Icosavax based?

Icosavax is headquartered in Seattle, United States, in the North America region.

How does Icosavax make money?

One revenue line is on record: vaccine Development and Commercialization.

Who are Icosavax's main competitors?

Direct peers on record are Novavax, Vaxcyte and Moderna. Emerging players are Bavarian Nordic, CureVac, Arcturus Therapeutics and Meissa Vaccines. Broad incumbents are Sanofi, Pfizer and GSK.

Does Icosavax have an API?

No public API is recorded for Icosavax.

What industry is Icosavax in?

Icosavax's product category is Infectious Disease Vaccine Development. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAIAEAD, Seasonal & Endemic Vaccines (e.g., Influenza). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldFormer Astrazeneca employee settles insider trading chargesThe U.S. SEC settled insider trading charges against Weiguo Zhai, a former Astrazeneca employee, related to the company's 2023 $1.1 billion acquisition of Icosavax. The settlement resolved charges without further details.The Daily RecordAstraZeneca employee in MD accused of insider tradingThe SEC filed a complaint against AstraZeneca employee Weiguo Zhai for insider trading, alleging he bought Icosavax shares before the company's $800 million acquisition. He sold them after the stock rose nearly 50%, realizing a $10,006 gain. The SEC seeks disgorgement and civil penalties.openPR.comMarket Driver Insights: The Impact of Recent Advances on the Human Metapneumovirus (hMPV) Therapeutics MarketThe human metapneumovirus (hMPV) therapeutics market is projected to grow to $0.94 billion by 2030, reflecting a compound annual growth rate of 6.0%, driven by increased R&D efforts, funding for respiratory virus research, and rising demand for treatments among immunocompromised patients. In February 2024, AstraZeneca plc acquired Icosavax, Inc. for $1.1 billion to integrate its virus-like particle technology and combination vaccine candidate targeting RSV and hMPV. The market is segmented by drug class, distribution channel, and end-use, with key players including Pfizer, Sanofi, Moderna, and Merck KGaA among others.ReutersAstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln dealAstraZeneca acquired respiratory vaccine developer Icosavax in a $1.1 billion cash deal, valuing the company at $15 a share plus up to $5 a share on milestones. The combination vaccine targets RSV and hMPV, with Icosavax reporting positive interim trial results. The deal aims to enter the multi-billion RSV market.BenzingaWhy Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Achieve LifeAstraZeneca announced plans to acquire Icosavax in a deal valued at up to $1.1 billion, causing Icosavax shares to rise nearly 45% in pre-market trading. The article also reports that Blue Bird Corporation saw its shares increase after reporting better-than-expected fourth-quarter financial results and raising its FY24 revenue forecast.GlobeNewswireIcosavax, Inc. Announces Agreement to be Acquired by AstraZenecaAstraZeneca agreed to acquire Icosavax for $15 per share in cash plus a contingent value right up to $5 per share, totaling up to $1.1 billion. The upfront cash represents a 43% premium over Icosavax's closing price, with the deal expected to close in Q1 2024.BenzingaWhy Respiratory Vaccine Player Icosavax (ICVX) Shares Are Surging Today - AstraZeneca (NYSE:AZN)AstraZeneca has agreed to acquire Icosavax Inc at $15.00 per share in cash, plus up to $5.00 per share in contingent value rights tied to regulatory and sales milestones, representing an equity value of approximately $838 million and a 43% premium over Icosavax's share price. The acquisition provides AstraZeneca access to Icosavax's experimental respiratory vaccines, including IVX-A12, which showed positive Phase 2 interim results for a combination vaccine targeting RSV and hMPV. The deal is expected to close in Q1 2024.AstrazenecaAstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II dataAstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc., a US-based clinical-stage biopharmaceutical company, for approximately $0.8 billion upfront in cash plus up to $1.1 billion in contingent payments tied to regulatory and sales milestones. The acquisition centers on Icosavax's lead vaccine candidate IVX-A12, a potential first-in-class combination protein VLP vaccine targeting both RSV and hMPV in adults 60+, which has demonstrated positive Phase II immunogenicity data and received Fast Track Designation from the FDA. The transaction, representing a 43% premium to Icosavax's closing price and 91% premium to its 60-day VWAP, is expected to close in Q1 2024 pending shareholder tender and regulatory conditions.GlobeNewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc. (NYSE - EGLE), Icosavax, Inc. (Nasdaq - ICVX), Evofem Biosciences, Inc. (OTC - EVFM),Brodsky & Smith notified investors of four investigations into alleged breaches of fiduciary duties by boards of Eagle Bulk, Icosavax, Evofem, and CapStar. The investigations question whether the boards failed to conduct fair processes and pay fair value in their respective acquisitions.BenzingaIcosavax Touts Encouraging Early-Cut Data From Phase 1 Trial Of RSV VaccineIcosavax Inc announced positive topline interim results from its Phase 1 trial of IVX-A12, a vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults, with the vaccine showing good tolerability and robust immune responses across all dosage groups. The company also priced a $67.8 million registered direct offering with healthcare investors and expects its cash balance to fund operations into the second half of 2025. Icosavax plans to initiate a Phase 2 trial in mid-2023 and conduct an hMPV human challenge clinical trial pending Phase 2 results.